Retroperitoneal lymph node dissection (RPLND) post chemotherapy for non-seminomatous testicular neoplasms: what is the significance of residual masses at scanner control after chemotherapy and should they be removed?
Solé-Balcells
F
F
Urology Service, Fundación Puigvert, Barcelona, Spain.
Villavicencio
H
H
Germá
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D011379:Prognosis; D012187:Retroperitoneal Space; D013724:Teratoma / Q000188:drug therapy / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology